Severe cardiac dysrhythmia in patients using bromocriptine postpartum.
Severe cardiac dysrhythmia in patients using bromocriptine postpartum.
复制标题
DOI：
10.1097/00045391-199803000-00010
复制
发表时间：
1998-03-01
影响因子：
4.2
通讯作者：
Hopp, L
中科院分区：
文献类型：
--
作者：
Iffy, L;O'Donnell, J;Hopp, L
自 1980 年以来，甲磺酸溴隐亭在全球范围内用于预防产褥期乳房肿胀，1994 年作为适合断奶的药物从美国市场撤出。美国食品和药物管理局的相关建议基于描述该药物使用者出现严重血管痉挛反应的病例报告。一些患者因此出现中风、颅内出血、脑水肿、抽搐、心肌梗塞和产后精神病。最近，有人提出该药物的副作用还可能包括继发于心律失常的循环衰竭。本报告描述了该类别中的另外两个案例。这些女性的产前临床评估表明她们容易出现心律失常。
Used worldwide since 1980 for the prevention of breast engorgement in the puerperium, in 1994 bromocriptine mesylate was withdrawn from the American market as an agent suitable for ablactation. The relevant recommendation of the Food and Drug Administration rested on case reports that described severe vasospastic reactions among users of the drug. Some patients so affected suffered stroke, intracranial bleeding, cerebral edema, convulsions, myocardial infarction, and puerperal psychosis. More recently, it has been suggested that the side effects of the drug may also include circulatory collapse secondary to cardiac dysrhythmia. This report describes two additional cases in this category. The antepartum clinical evaluation of these women suggested that they were predisposed to arrhythmias.